Q1. In the WHO's 2026 tuberculosis diagnostic recommendations, which one of the following best describes a 'near point-of-care nucleic acid amplification test (NPOC-NAAT)'?
- A. A molecular test for the initial detection of TB deployable at peripheral levels of the health system at lower unit cost than other molecular instruments
- B. A lateral-flow antigen test that detects lipoarabinomannan in urine for TB screening in HIV patients
- C. A centralised cartridge-based PCR platform requiring a controlled laboratory environment to detect rifampicin resistance
- D. An AI software package that reads digital chest X-rays to flag presumptive TB cases